Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
1993-12-23
|
| pubmed:abstractText |
A phase I study was performed to describe the principal toxicities and identify the maximum-tolerated dose (MTD) of Taxol (paclitaxel; Bristol-Myers Squibb Co, Wallingford, CT) in children with therapy-resistant solid tumors. Additionally, the pharmacokinetic disposition of Taxol in children was studied, and preliminary evidence of the activity of Taxol against pediatric solid tumors was assessed.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0732-183X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
11
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2324-9
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:7902425-Adolescent,
pubmed-meshheading:7902425-Adult,
pubmed-meshheading:7902425-Child,
pubmed-meshheading:7902425-Child, Preschool,
pubmed-meshheading:7902425-Female,
pubmed-meshheading:7902425-Humans,
pubmed-meshheading:7902425-Infusions, Intravenous,
pubmed-meshheading:7902425-Male,
pubmed-meshheading:7902425-Neoplasms,
pubmed-meshheading:7902425-Paclitaxel,
pubmed-meshheading:7902425-Treatment Outcome
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study.
|
| pubmed:affiliation |
Department of Hematology/Oncology, St Jude Children's Research Hospital, Memphis, TN.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|